At XP Pharma Consulting, we help you translate preclinical discovery data into actionable clinical strategies that support a successful IND submission (PK/PD analysis for IND submissions). Our team bridges nonclinical and clinical pharmacology through modeling, simulation, and regulatory alignment to ensure your first-in-human studies are scientifically sound and submission-ready.

Our expertise includes:

• Noncompartmental PK Analysis (NCA) – validated analysis, proportionality assessment, and submission-ready reports.
• PK/PD Modeling and Simulation – integrating nonclinical PK/PD data, allometric scaling, dose justification, and human exposure prediction.
• Clinical Pharmacology Strategy and Writing – gap analyses, clinical pharmacology plans, IND protocols, and responses to regulatory queries.

From preclinical data interpretation to IND dossier preparation, we guide you through each decision point with clear, quantitative insight.

In early clinical development, XP Pharma Consulting helps you design and execute studies that efficiently generate the data needed to support dose selection, safety characterization, and proof of concept. We integrate pharmacokinetic and pharmacodynamic insight with regulatory expectations to ensure every study fits seamlessly into your broader development strategy.

Our support includes:

• Noncompartmental PK Analysis (NCA) – validated tools for early PK assessment, dose proportionality, and exposure–response evaluation, delivering submission-ready reports.
• PK/PD Modeling & Simulation – population PK and exposure–response modeling, concentration-QT analysis, dose simulations for different populations and formulations, and covariate identification for later-phase optimization.
• Clinical Pharmacology Strategy and Writing – clinical pharmacology plans, study protocols, PK/PD report authoring, dose rationale, and expert responses to regulatory queries and meetings.

From first-in-human to Phase 2a, we guide your early studies with precision and foresight — helping you move confidently toward pivotal trials.

At the pivotal stage of development, XP Pharma Consulting supports you in designing and interpreting complex studies that define the efficacy, safety, and exposure–response profile of your drug. We use advanced quantitative tools and regulatory experience to help you build a robust clinical pharmacology package for NDA/BLA submission.
Our team applies modeling and simulation to justify labeling doses, anticipate regulatory expectations, support pediatric strategies, and streamline development by reducing the need for additional late-phase studies.

Our services include:

• Noncompartmental PK Analysis (NCA) – validated software-based analyses, study protocol support, exposure–response evaluations, and submission-ready reports.
• PK/PD Modeling & Simulation, model-informed drug development consulting – dose optimization, TQT waiver justification, bridging strategies to pediatric populations, population PK and exposure–response modeling, and risk assessments for QT prolongation potential.
• Clinical Pharmacology Strategy and Writing – clinical pharmacology plans, study protocol development and reviews, regulatory document preparation, expert meeting representation, and comprehensive response authoring to regulatory agencies.

Through precise modeling, data interpretation, and clear regulatory communication, we help you complete late-phase studies with confidence and prepare for a successful submission.

After completing early and late-phase studies, you’ve invested years of work and resources to bring your program to this critical point. XP Pharma Consulting partners with you to prepare the clinical pharmacology sections of your NDA/BLA submission, conduct integrated analyses, and provide clear, data-driven responses to regulatory agencies – regulatory strategy consulting for NDA/BLA.

Our team combines deep pharmacometric expertise with regulatory experience to ensure your submission meets FDA and EMA expectations, presenting a coherent, scientifically sound justification for dose selection, labeling, and risk assessment.

Our services include:

• Regulatory Writing and Strategy – authoring CTD sections m2.7.1, m2.7.2, and contributing to m2.5 (biopharmaceutics, clinical pharmacology, dose justification), as well as selected parts of m2.7.3 and m2.7.4. Development of PK/PD labeling text, integrated PK and PK/PD analyses, immunogenicity reports, and scientific publications (manuscripts, posters, conference materials).
• Ad-Hoc PK/PD Analyses – pooled and integrated PK/PD and immunogenicity analyses, QT risk evaluations, and interpretation of complex clinical datasets to support data consistency across studies.
• Regulatory Interactions – preparation of written responses to agency queries, representation during regulatory meetings, and on-demand quantitative analyses to address questions during the review phase.

With XP Pharma Consulting, your submission benefits from scientific clarity, regulatory precision, and end-to-end support through approval.